Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELARA: Aflibercept 8 mg in nAMD or DME
NCT06491914Phase 3Active, not recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jul 2024
- Primary completion
- Aug 2025
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of aflibercept in neovascular age-related macular degeneration (NVAMD) and diabetic macular edema (DME), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Treatment-emergent Adverse Events at 24 weeks and Serious Treatment-emergent Adverse Events at 24 weeks. Started Jul 2024; status: active, not recruiting.
02
Drugs
aflibercept
03
Conditions
neovascular age-related macular degeneration (NVAMD)diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT06491914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06491914.